These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21756413)

  • 1. Interactions between health technology assessment, coverage, and regulatory processes: emerging issues, goals, and opportunities.
    Henshall C; Mardhani-Bayne L; Frønsdal KB; Klemp M
    Int J Technol Assess Health Care; 2011 Jul; 27(3):253-60. PubMed ID: 21756413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry.
    Frønsdal K; Pichler F; Mardhani-Bayne L; Henshall C; Røttingen JA; Mørland B; Klemp M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):374-81. PubMed ID: 23062516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive approaches to licensing, health technology assessment, and introduction of drugs and devices.
    Husereau D; Henshall C; Jivraj J
    Int J Technol Assess Health Care; 2014 Jul; 30(3):241-9. PubMed ID: 24921416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involving stakeholders and developing a policy for stakeholder involvement in the European network for health technology assessment, EUnetHTA.
    Nielsen CP; Lauritsen SW; Kristensen FB; Bistrup ML; Cecchetti A; Turk E;
    Int J Technol Assess Health Care; 2009 Dec; 25 Suppl 2():84-91. PubMed ID: 20030895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harmonization of evidence requirements for health technology assessment in reimbursement decision making.
    Hutton J; Trueman P; Facey K
    Int J Technol Assess Health Care; 2008; 24(4):511-7. PubMed ID: 18828948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using health technology assessment to support optimal use of technologies in current practice: the challenge of "disinvestment".
    Henshall C; Schuller T; Mardhani-Bayne L
    Int J Technol Assess Health Care; 2012 Jul; 28(3):203-10. PubMed ID: 22792877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
    Oortwijn W; Mathijssen J; Banta D
    Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health technology assessment, value-based decision making, and innovation.
    Henshall C; Schuller T;
    Int J Technol Assess Health Care; 2013 Oct; 29(4):353-9. PubMed ID: 23845404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IMPROVING THE EFFECTIVENESS AND EFFICIENCY OF EVIDENCE PRODUCTION FOR HEALTH TECHNOLOGY ASSESSMENT.
    Facey K; Henshall C; Sampietro-Colom L; Thomas S
    Int J Technol Assess Health Care; 2015 Jan; 31(4):201-6. PubMed ID: 26646858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health technology assessment to optimize health technology utilization: using implementation initiatives and monitoring processes.
    Frønsdal KB; Facey K; Klemp M; Norderhaug IN; Mørland B; Røttingen JA
    Int J Technol Assess Health Care; 2010 Jul; 26(3):309-16. PubMed ID: 20584360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early assessment of medical technologies to inform product development and market access: a review of methods and applications.
    Ijzerman MJ; Steuten LM
    Appl Health Econ Health Policy; 2011 Sep; 9(5):331-47. PubMed ID: 21875163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing Health Technology Assessment to address health care system needs.
    Velasco Garrido M; Gerhardus A; Røttingen JA; Busse R
    Health Policy; 2010 Mar; 94(3):196-202. PubMed ID: 19889471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New trends and challenges in the European regulation of innovative medicines.
    Enzmann H
    Regul Toxicol Pharmacol; 2016 Oct; 80():314-20. PubMed ID: 27237379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health technology assessment: research trends and future priorities in Europe.
    Nielsen CP; Funch TM; Kristensen FB
    J Health Serv Res Policy; 2011 Jul; 16 Suppl 2():6-15. PubMed ID: 21737525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A regulatory governance perspective on Health Technology Assessment (HTA) in Sweden.
    Shah SM; Barron A; Klinger C; Wright JS
    Health Policy; 2014 May; 116(1):27-36. PubMed ID: 24655685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-based health technology assessment: a vision of the future.
    Bridges JF; Jones C
    Int J Technol Assess Health Care; 2007; 23(1):30-5. PubMed ID: 17234014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Confluence of Accelerated Regulatory and Health Technology Assessment Access Pathways.
    McAuslane N; Liberti L; Connelly P
    Clin Pharmacol Ther; 2019 Apr; 105(4):935-942. PubMed ID: 30472729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A regulatory governance perspective on health technology assessment (HTA) in France: the contextual mediation of common functional pressures.
    Barron AJ; Klinger C; Shah SM; Wright JS
    Health Policy; 2015 Feb; 119(2):137-46. PubMed ID: 25458970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.